Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

This study is looking for adults aged between 18 and 90 years old who have had an ischaemic stroke recently. You need to have received treatment for your stroke within 24 hours of it starting. Your stroke symptoms should be moderate, not too mild or too severe. Before your stroke, you should have been generally healthy and able to care for yourself without much help.

There are also specific situations where you might be considered. For example, if you initially had milder symptoms but they got worse, or if you had clot-busting treatment but your stroke symptoms didn't improve much after at least six hours, and you still have moderate symptoms. Importantly, you shouldn't have had a brain bleed (haemorrhagic stroke) and you shouldn't be eligible for, or have had, mechanical thrombectomy (a procedure to remove a large clot).

If you're interested, you and/or your legal representative must be able to understand the study and agree to take part. You also need to be willing to follow the study's instructions. Your doctor will carefully check if you meet all the criteria.

If you join the study, you'll be randomly assigned to either receive the study medicine, DM199, or a placebo (a dummy medicine). You won't know which one you're getting, and neither will your care team. DM199 is given in two ways: first, as a single dose into a vein, and then as injections under the skin twice a week for up to 21 days.

Throughout the study, you'll have regular check-ups and assessments to monitor your health, how your stroke is recovering, and to check for any side effects. This will involve visits to the hospital or clinic. Your participation in the study from the first treatment to the final assessments will last for approximately 90 days (about three months).